2025 Annual President's Work Report of China Resources Boya Biopharmaceutical Group Co., Ltd.
In 2025, the pharmaceutical industry faced multiple challenges, including the deepening expansion of centralized procurement, tightening regulations, a complex and volatile market environment, and increasing public opinion risks. Particularly, with the ongoing DRG/DIP payment reform, clinical medication behaviors have become more standardized, and hospital prescription behaviors have become more cautious. The space for off-label and off-indication drug use continues to narrow, putting pressure on both the volume and price of blood products in the short term. In the long term, this compels the industry to undergo a survival of the fittest, gradually increasing industry concentration, enriching product lines, and building academic promotion capabilities to promote cost reduction through scale effects to address industry challenges. Against this backdrop, the management team and all employees of China Resources Boya Biopharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") have, under the leadership of the Board of Directors, overcome various adverse factors affecting development, united in purpose, and made progress. They strictly adhered to the requirements of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Articles of Association, implementing the resolutions of the shareholders' meeting and the Board of Directors, focusing on the main responsibilities and businesses of blood products, scientifically formulating and implementing the annual business plan, continuously optimizing the governance system and operational mechanisms, and carrying out various tasks in an orderly manner, successfully completing all work for 2025. The President of the Company presents the 2025 Annual President's Work Report to the Board of Directors, as follows:
1. 2025 Business Performance Report
During the reporting period, the Company achieved operating revenue of 2,059.088 million yuan, a year-on-year increase of 18.69%; total profit was 103.8785 million yuan, a year-on-year decrease of 78.26%. Among these, the parent company achieved operating revenue of 1,413.844 million yuan, a year-on-year decrease of 4.08%; total profit was 180.3163 million yuan, a year-on-year decrease of 61.63%. The net profit attributable to shareholders of the listed company was 112.6983 million yuan, a year-on-year decrease of 71.61%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -7.7575 million yuan, a year-on-year decrease of 102.57%. In 2025, the Company continued to integrate internal and external resources, successfully promoted the expansion of the Yangcheng plasma station, and included Qinxian County in its plasma collection range. The potential of the plasma station was deeply explored, with a total plasma collection of 662.31 tons for the year (of which China Resources Boya Biopharmaceutical collected 542.4 tons (+3.97%), and Green Cross collected 119.91 tons (+10.46%)), a year-on-year increase of 5.03%, setting a new historical high, further enhancing the raw plasma supply capacity. At the same time, the collection rate of core products steadily improved, and the output value continued to grow. The R&D pipeline was continuously expanded, with the production approval of 10% intravenous immunoglobulin and tetanus immunoglobulin, and clinical approval for 20% subcutaneous immunoglobulin. Additionally, internationalization also made positive progress, with intravenous immunoglobulin obtaining registration in the Dominican Republic, and overseas technology and system output projects progressing in an orderly manner.